Key presentations include:
Oral presentation: “Early Development of ALKS 3831: A Novel Drug
Candidate for the Treatment of Schizophrenia” will be given by
Poster 84: “Early Development of ALKS 3831: A Novel Drug Candidate for
the Treatment of Schizophrenia” will be presented by
Poster 79: “A Randomized, Double-Blind, Placebo-Controlled Trial to
Evaluate the Safety and Efficacy of ALKS 3831 in the Prevention of
Olanzapine-Induced Weight Gain in Healthy Male Volunteers” will be
presented by
Oral presentation: “Opioid Modulation: A Novel Mechanism for the
Treatment of Depression: Results of the ALKS 5461 Phase 2 Study” will be
given by
A full list of all
About ALKS 5461
ALKS 5461 is a proprietary investigational medicine with a novel mechanism for the treatment of major depressive disorder (MDD). The mechanism of action for ALKS 5461 in the treatment of depressive symptoms is based on modulation of the opioid system in the brain, employing a balanced combination of agonism and antagonism of opioid receptors. ALKS 5461 consists of buprenorphine, a partial agonist, and ALKS 33, a potent mu-opioid antagonist, and is designed to be a once-daily, non-addictive medicine.
About ALKS 3831
ALKS 3831 is a proprietary investigational medicine designed as a broad spectrum treatment for schizophrenia. ALKS 3831 is comprised of ALKS 33, a novel opioid modulator that acts as a potent mu-opioid antagonist, in combination with the established antipsychotic drug, olanzapine. ALKS 3831 is designed to attenuate olanzapine-induced metabolic side effects, including weight gain, and offer the therapeutic benefits of olanzapine to a wider range of patients with schizophrenia. ALKS 3831 will also be studied to evaluate its utility in patients with schizophrenia and comorbid substance abuse.
About New Clinical Drug Evaluation Unit (NCDEU) Meeting
NCDEU is a scientific meeting that focuses on the latest developments in
psychopharmacologic clinical research and related methodology. The
meeting brings together over 1,200 academic and industry investigators,
research pharmacists, nurses, social workers, psychologists and other
clinicians. NCDEU focuses on timely issues in psychiatric clinical
research and includes presentations and information from the
About
Note Regarding Forward-Looking Statements
Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning the therapeutic value of the company’s products. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond the company’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements.
These risks and uncertainties include, among others, whether the results
of the company’s clinical development activities will be predictive of
real-world results or of results in subsequent clinical trials; and
those risks described in the company’s Annual Report on Form 10-K for
the year ended
Source:
Alkermes Contacts:
For Investors:
Rebecca Peterson, +1
781-609-6378
or
For Media:
Jennifer Snyder, +1
781-609-6166